Abstract：Objective To summarize the recent pharmacological research progress and clinical use of Multi-glycoside of Tripterygium WilfordiHook,f.(GTW). MethodsWe collected the latest researches related to the pharmacological reaction and clinical use of GTW, and then gave the analysis and summary. Results and ConclusionTriptolide, as the major active component of GTW, is converted into metabolites in vivothrough cytochrome P450 system. Triptolide has the effect of anti-inflammation, immunosuppression, and podocyte protection, etc. GTW can effectively reduce proteinuria when used in treating primary or secondary glomerulonephritis. The main adverse reactions are genital system damage and renal or hepatic damage. GTW is cheap and has a high cost-benefit ratio. But the pharmaceutical quality of GTW is unstable, which impactsits clinical use.
张鑫，武祯，李航. 雷公藤多甙片药理学研究进展及临床应用[J]. 临床药物治疗杂志, 2014, 12(4): 8-13.
zhangxin，wuzhen,lihang. A Review of Pharmacological Research Progress and Clinical Use on Multi-glycoside of Tripterygium wilfordiHook,f Tablet. CLINICAL MEDICATION JOURNAL, 2014, 12(4): 8-13.
[1] 邵凤, 王广基, 孙建国, 等. 雷公藤内酯醇在Beagle犬体内的药代动力学[J]. 药学学报, 2007(01):61-65.
[2] Shao F, Wang G, Xie H, et al. Pharmacokinetic study oftriptolide, a constituent of immunosuppressive chinese herbmedicine, in rats[J]. Biol Pharm Bull, 2007, 30(4):702-707.
[3] 刘萍霞，刘频健，庄笑梅，等. 抗肿瘤化合物MC002的活性代谢产物雷公藤内酯醇在大鼠体内药代动力学与组织分布[J].中国药理学与毒理学杂志, 2011(02):206-210.
[4] Zhou Z, Yang Y, Ding J, et al. Triptolide: structural modifications,structure–activity relationships, bioactivities, clinicaldevelopment and mechanisms[J]. Nat Prod Rep, 2012,29(4):457.
[5] Li W, Liu Y, He Y Q, et al. Characterization of triptolidehydroxylation by cytochrome P450 in human and rat livermicrosomes[J]. Xenobiotica, 2008, 38(12):1551-1565.
[6] Xue X, Gong L, Qi X, et al. Knockout of hepatic P450 reductaseaggravates triptolide-induced toxicity[J]. Toxicol Lett, 2011,205(1):47-54.
[7] Ye X, Li W, Yan Y, et al. Effects of cytochrome P4503A inducerdexamethasone on the metabolism and toxicity of triptolide inrat[J]. Toxicol Lett, 2010, 192(2):212-220.
[8] 李学旺. 中药雷公藤在慢性肾脏疾病治疗中的应用[J]. 肾脏病与透析肾移植杂志, 2003(03):251-252.
[9] 王畅, 梁倩, 彭佑铭, 等. 雷公藤甲素对IgA肾病患者外周血单个核细胞炎性反应及凋亡的影响[J]. 中华肾脏病杂志,2011, 27(10):724-729.
[10] Titov D V, Gilman B, He Q, et al. XPB, a subunit of TFIIH, isa target of the natural product triptolide[J]. Nature Chem Biol2011, 7(3):182-188.
[11] Manzo S G, Zhou Z L, Wang Y Q, et al. Natural product triptolidemediates cancer cell death by triggering CDK7-dependentdegradation of RNA polymerase II[J]. Cancer Res, 2012,72(20):5363-5373.
[12] 秦卫松，刘志红，曾彩虹，等. 雷公藤甲素对Heymann肾炎模型足细胞病变的影响[J]. 肾脏病与透析肾移植杂志,2007(02):101-109.
[13] Chen Z, Qin W, Zeng C, et al. Triptolide reduces proteinuriain experimental membranous nephropathy and protects againstC5b-9-induced podocyte injury in vitro[J]. Kidney Int, 2010,77(11):974-988.
[14] 陈朝红，洪亦眉，秦卫松，等. 雷公藤甲素对血管紧张素Ⅱ诱导足细胞损伤的保护作用及其机制研究[J]. 肾脏病与透析肾移植杂志, 2010, 19(6):508-515.
[15] Ma R, Liu L, Liu X, et al. Triptolide markedly attenuatesalbuminuria and podocyte injury in an animal model ofdiabetic nephropathy[J]. Exp Ther Med, 2013,6(3):649-656.
[16] Wan Y, Sun W, Zhen Y, et al. Multi-glycoside of Tripterygiumwilfordii Hook. f. reduces proteinuria through improvingpodocyte slit diaphragm dysfunction in anti-Thy1.1glomerulonephritis[J]. J Ethnopharmacol, 2011, 136(2):322-333.
[17] 黎磊石，刘志红. 应用雷公藤治疗肾炎二十五载的体会[J].肾脏病与透析肾移植杂志, 2003, (03):246-247.
[18] Zhu B, Wang Y, Jardine M, et al. Tripterygium preparationsfor the treatment of CKD: a systematic review and metaanalysis[J]. Am J Kidney Dis, 2013, 62(3):515-530.
[19] Chen Y, Gao Q, Zhao X, et al. Meta-Analysis of TripterygiumWilfordii Hook F in the Immunosuppressive Treatment of IgANephropathy[J]. Internal Med, 2010, 49(19):2049-2055.
[20] 范德墉, 叶朝阳, 戎殳, 等. 中等量蛋白尿IgA肾病糖皮质激素与雷公藤治疗对比观察[J]. 中国中西医结合肾病杂志,2008, 9(1):45-46.
[21] 冯忖. 雷公藤多甙联合小剂量糖皮质激素治疗IgA肾病的临床疗效观察[J]. 中国中医基础医学杂志, 2013(05):529-530.
[22] 刘志红, 李世军, 吴燕, 等. 雷公藤多苷联合小剂量激素治疗特发性膜性肾病前瞻性对照研究[J]. 肾脏病与透析肾移植杂志, 2009(04):303-309.
[23] 孙铁忠，何晓芳. 雷公藤多甙与环磷酰胺分别联合泼尼松治疗特发性膜性肾病疗效比较[J]. 武警后勤学院学报(医学版), 2012(09):678-681.
[24] Tang X, Xu F, Chen D, et al. The clinical course and long-termoutcome of primary focal segmental glomerulosclerosis inChinese adults[J]. Clin Nephrol, 2013, 80(08):130-139.
[25] 刘正钊, 胡伟新, 章海涛, 等. 激素联合雷公藤多苷治疗V型狼疮性肾炎的临床疗效[J]. 肾脏病与透析肾移植杂志,2008(06):512-516.
[26] Ge Y, Xie H, Li S, et al. Treatment of diabetic nephropathy withTripterygium wilfordii Hook F extract: a prospective, randomized,controlled clinical trial[J]. J Transl Med, 2013, 11(1):134.
[27] Wu L, Mao J, Jin X, et al. Efficacy of Triptolide for Childrenwith Moderately Severe Henoch-Sch?nlein Purpura NephritisPresenting with Nephrotic Range Proteinuria: A Prospectiveand Controlled Study in China[J]. Biomed Res Int, 2013,(2013):292-865.
[28] 国家食品药品监督管理局. 关注雷公藤制剂的用药安全[Z]药品不良反应信息通报(第46期), 2012.
[29] 李原丽, 覃筱芸. 雷公藤294例不良反应的文献调查与分析[J]. 山西医药杂志, 2011(01):88-90.
[30] 张洁, 段宏泉. 紫外分光光度法测定雷公藤多苷片和不同产地药材中总生物碱的含量[J]. 天津医科大学学报,2009(03):354-356
2014, Vol. 12 
